PriMera Scientific Surgical Research and Practice (ISSN: 2836-0028)


Volume 3 Issue 2

Expanding the Horizons of Theranostics Beyond Oncology - Lessons from PSMA

Subhash Chnad Kheruka*, Anjali Jain, Naema Almaymani, Noura Makhmari, Khulood Al Riyami, Rashid ALSukaiti

January 29, 2024

DOI : 10.56831/PSSRP-03-083


The term "theranostics" has transcended its status as a mere buzzword in the realm of nuclear medicine, thanks largely to the groundbreaking advancements in prostate-specific membrane antigen (PSMA)–targeted radioligands. These radioligands, which can be labeled with either positron- or γ-emitting isotopes for imaging or with β- or α-emitting isotopes for therapy, have revolutionized prostate cancer management over the past decade. Their success has not only led to the rapid adoption of PSMA-targeted imaging and therapy as a new clinical standard but also inspired exploration into other diseases. This development begs the question: What makes PSMA theranostics so successful, and how can these principles be applied to other areas in nuclear medicine?.


  1. Langbein T, Weber WA and Eiber M. “The Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine”. Journal of Nuclear Medicine 60.Suppl 2 (2019): 13S-19S.
  2. Feinstein AR, Sosin DM and Wells CK. “The Will Rogers Phenomenon: Stage Migration and New Diagnostic Techniques as a Source of Misleading Statistics for Survival in Cancer”. New England Journal of Medicine 312 (1985): 1604-1608.
  3. Fischer B., et al. “Preoperative Staging of Lung Cancer with Combined PET-CT”. New England Journal of Medicine 361 (2009) 32-39.
  4. Bukavina L., et al. “Incorporating Prostate-Specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer”. European Urology (2022).
  5. Horn T., et al. “Single Lesion on Prostate-Specific Membrane Antigen-Ligand Positron Emission Tomography and Low Prostate-Specific Antigen are Prognostic Factors for a Favorable Biochemical Response to Prostate-Specific Membrane Antigen-Targeted Radioguided Surgery in Recurrent Prostate Cancer”. European Urology 76 (2019): 517-523.
  6. US VA to Cover Eisai, Biogen Alzheimer’s Treatment Leqembi. Reuters (2023).